689 related articles for article (PubMed ID: 17287448)
1. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.
Fleisher AS; Sowell BB; Taylor C; Gamst AC; Petersen RC; Thal LJ;
Neurology; 2007 May; 68(19):1588-95. PubMed ID: 17287448
[TBL] [Abstract][Full Text] [Related]
2. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment.
Fleisher AS; Sun S; Taylor C; Ward CP; Gamst AC; Petersen RC; Jack CR; Aisen PS; Thal LJ
Neurology; 2008 Jan; 70(3):191-9. PubMed ID: 18195264
[TBL] [Abstract][Full Text] [Related]
3. Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia.
van Straaten EC; Harvey D; Scheltens P; Barkhof F; Petersen RC; Thal LJ; Jack CR; DeCarli C;
J Neurol; 2008 Sep; 255(9):1302-8. PubMed ID: 18825439
[TBL] [Abstract][Full Text] [Related]
4. Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment.
Whitehair DC; Sherzai A; Emond J; Raman R; Aisen PS; Petersen RC; Fleisher AS;
Alzheimers Dement; 2010 Sep; 6(5):412-9. PubMed ID: 20813342
[TBL] [Abstract][Full Text] [Related]
5. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
De Beaumont L; Pelleieux S; Lamarre-Théroux L; Dea D; Poirier J;
J Alzheimers Dis; 2016 Oct; 54(3):913-922. PubMed ID: 27567841
[TBL] [Abstract][Full Text] [Related]
6. Vitamin E and donepezil for the treatment of mild cognitive impairment.
Petersen RC; Thomas RG; Grundman M; Bennett D; Doody R; Ferris S; Galasko D; Jin S; Kaye J; Levey A; Pfeiffer E; Sano M; van Dyck CH; Thal LJ;
N Engl J Med; 2005 Jun; 352(23):2379-88. PubMed ID: 15829527
[TBL] [Abstract][Full Text] [Related]
7. Donepezil versus vitamin E in Alzheimer's disease: Part 2: mild versus moderate-severe Alzheimer's disease.
Onofrj M; Thomas A; Luciano AL; Iacono D; Di Rollo A; D'Andreamatteo G; Di Iorio A
Clin Neuropharmacol; 2002; 25(4):207-15. PubMed ID: 12151908
[TBL] [Abstract][Full Text] [Related]
8. Donepezil delays progression to AD in MCI subjects with depressive symptoms.
Lu PH; Edland SD; Teng E; Tingus K; Petersen RC; Cummings JL;
Neurology; 2009 Jun; 72(24):2115-21. PubMed ID: 19528519
[TBL] [Abstract][Full Text] [Related]
9. The importance of Alzheimer disease assessment scale-cognitive part in predicting progress for amnestic mild cognitive impairment to Alzheimer disease.
Rozzini L; Vicini Chilovi B; Bertoletti E; Conti M; Delrio I; Trabucchi M; Padovani A
J Geriatr Psychiatry Neurol; 2008 Dec; 21(4):261-7. PubMed ID: 19017783
[TBL] [Abstract][Full Text] [Related]
10. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
[TBL] [Abstract][Full Text] [Related]
11. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study.
Sarazin M; Berr C; De Rotrou J; Fabrigoule C; Pasquier F; Legrain S; Michel B; Puel M; Volteau M; Touchon J; Verny M; Dubois B
Neurology; 2007 Nov; 69(19):1859-67. PubMed ID: 17984454
[TBL] [Abstract][Full Text] [Related]
12. Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.
Kudoh C; Arita R; Honda M; Kishi T; Komatsu Y; Asou H; Mimura M
Psychogeriatrics; 2016 Mar; 16(2):85-92. PubMed ID: 25918972
[TBL] [Abstract][Full Text] [Related]
13. Cognitive predictors of donepezil therapy response in Alzheimer disease.
Saumier D; Murtha S; Bergman H; Phillips N; Whitehead V; Chertkow H
Dement Geriatr Cogn Disord; 2007; 24(1):28-35. PubMed ID: 17495473
[TBL] [Abstract][Full Text] [Related]
14. The hard Test Your Memory. Evaluation of a short cognitive test to detect mild Alzheimer's disease and amnestic mild cognitive impairment.
Brown JM; Wiggins J; Dong H; Harvey R; Richardson F; Hunter K; Dawson K; Parker RA
Int J Geriatr Psychiatry; 2014 Mar; 29(3):272-80. PubMed ID: 23929807
[TBL] [Abstract][Full Text] [Related]
15. APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease.
Waring JF; Tang Q; Robieson WZ; King DP; Das U; Dubow J; Dutta S; Marek GJ; Gault LM
J Alzheimers Dis; 2015; 47(1):137-48. PubMed ID: 26402762
[TBL] [Abstract][Full Text] [Related]
16. Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment.
Tabert MH; Manly JJ; Liu X; Pelton GH; Rosenblum S; Jacobs M; Zamora D; Goodkind M; Bell K; Stern Y; Devanand DP
Arch Gen Psychiatry; 2006 Aug; 63(8):916-24. PubMed ID: 16894068
[TBL] [Abstract][Full Text] [Related]
17. A 'Framingham-like' Algorithm for Predicting 4-Year Risk of Progression to Amnestic Mild Cognitive Impairment or Alzheimer's Disease Using Multidomain Information.
Steenland K; Zhao L; John SE; Goldstein FC; Levey A; Alvaro A;
J Alzheimers Dis; 2018; 63(4):1383-1393. PubMed ID: 29843232
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
[TBL] [Abstract][Full Text] [Related]
19. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
[TBL] [Abstract][Full Text] [Related]
20. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
